Accord BioPharma is the U.S. specialty business of Intas Pharmaceuticals, focused on biosimilars, generics, and specialty pharma products. In 2026, the company launched ENNUMO (pegfilgrastim-pccg), its second pegfilgrastim biosimilar, expanding its oncology supportive-care portfolio.